Lyell Immunopharma, Inc.
NASDAQ:LYELBiotechnology
+$0.15 today
- Market cap
- $341.49M
- Beta
- -0.09
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$11.26
Volume 0.11M
Average 0.09M
LYEL Account Payables
Amounts the company owes suppliers for goods and services received.
Lyell Immunopharma, Inc.NASDAQ: LYEL
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 46.7% from a year ago
Account payables stood at $5.47M at the end of Q1 FY2026, up 46.7% from a year earlier and up 89.0% from the prior quarter. Over 3 fiscal years it compounded at -9.6% a year.
Context
- Account payables amounted to 1.6% of total assets at the end of Q1 FY2026, up 0.7 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +46.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 2.89M USD
- Year-over-year change
- -46.1%
- 4-year CAGR
- -2.5%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.89M | -46.1% |
| FY2024 | 2024-12-31 | 5.37M | +11.4% |
| FY2023 | 2023-12-31 | 4.82M | +23.0% |
| FY2022 | 2022-12-31 | 3.92M | +22.1% |
| FY2021 | 2021-12-31 | 3.21M | — |
Account Payables vs competitors
How LYEL compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +46.7% is the 2nd highest of 11, against a peer median of -5.7%.
- Account payables amounts to 1.6% of total assets for LYEL, versus a peer median of 4.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $48.15M USD | +5.5% | -11.1% | 7.5% | |
| Mar 2026 | $11.6M USD | +37.0% | +54.1% | 4.5% | |
| Mar 2026 | $10.37M USD | -44.9% | +11.4% | 9.0% | |
| Mar 2026 | $8.58M USD | +277.1% | +45.7% | 4.1% | |
| Mar 2026 | $6.38M USD | -1.7% | +39.1% | 4.3% | |
GNLXGenelux Corporation | Mar 2026 | $6.1M USD | -8.9% | -13.7% | 18.8% |
| Mar 2026 | $5.47M USD | +46.7% | -9.6% | 1.6% | |
| Mar 2026 | $4.93M USD | -2.5% | -32.5% | 1.2% | |
| Mar 2026 | $4.33M USD | -20.7% | -35.1% | 2.9% | |
| Mar 2026 | CHF 1.32M CHF | -44.8% | +30.6% | 1.0% | |
| Mar 2026 | $141.36K USD | -59.2% | +5.8% | 0.2% | |
| Peer median (excluding LYEL) | — | -5.7% | +8.6% | 4.2% | |
Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 293.83M | 123.55M | 145.65M | 105.6M | 60.18M |
| Short-term Investments | 320.97M | 516.6M | 400.58M | 264.93M | 187.04M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 11.14M | 8.46M | 9.07M | 13.72M |
| Total Current Assets | 626.29M | 651.3M | 554.69M | 379.59M | 260.94M |
| Property, Plant & Equipment (Net) | 166.64M | 166.27M | 142.32M | 72.94M | 53.64M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 330.53M | 115.04M | 48.51M | 32.01M | 19M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.95M | 4.96M | 4.52M | 6.31M | 6.47M |
| Total Non-current Assets | 501.12M | 286.27M | 195.34M | 111.27M | 79.11M |
| Total Assets | 1.13B | 937.56M | 750.03M | 490.86M | 340.05M |
| Account Payables | 3.21M | 3.92M | 4.82M | 5.37M | 2.89M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 4.99M | 0 | 0 | 0 | 2.54M |
| Other Current Liabilities | 28.25M | 22.16M | 8.8M | 22.72M | 13.71M |
| Total Current Liabilities | 46.74M | 37.03M | 34.52M | 53.79M | 49.41M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 79.67M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 4.57M | 4.11M | 3.66M | 3.25M | 517K |
| Total Non-current Liabilities | 150.88M | 67.28M | 60.56M | 54.25M | 42.44M |
| Total Liabilities | 197.62M | 104.31M | 95.08M | 108.04M | 91.85M |
| Common Stock | 24K | 25K | 25K | 29K | 2K |
| Retained Earnings | (584.36M) | (767.48M) | (1B) | (1.35B) | (1.62B) |
| Accumulated OCI | (1.62M) | (7.6M) | (94K) | 291K | 242K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 929.79M | 833.25M | 654.95M | 382.82M | 248.2M |
| Total Debt | 67.82M | 67.7M | 63.17M | 58.97M | 50.99M |
| Net Debt | (226.01M) | (55.85M) | (82.48M) | (46.63M) | (9.19M) |
Lyell Immunopharma, Inc.
NASDAQ:LYEL
Intrinsic Alpha fair value
Locked
Current Price
$13.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.